Popular Articles
Cellulite Treatment

Acceleron And Celgene Initiate Phase 2 Study Of ACE-011 To Treat Chemotherapy-Induced Anemia
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone and muscle, and Celgene Corporation (NASDAQ: CELG) announced the initiation of a second Phase 2 clinical study of ACE-011. This Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the potential of ACE-011 to treat chemotherapy-induced anemia in patients with metastatic breast cancer. ACE-011 is a novel therapeutic agent that has been shown to increase levels of red blood cells and hemoglobin and stimulate new bone formation. ACE-011 works through a novel mechanism by inhibiting certain members of the TGF-beta superfamily while potentially avoiding the erythropoietin pathway.
generic viagra online Hotel dnister in the historical center.
Automated 'Artificial Pancreas' Controls Blood Glucose Levels In Diabetes Patients For First Time
UC Santa Barbara and Sansum Diabetes Research Institute scientists have demonstrated for the first time that an automated artificial pancreas system (APS) can safely and effectively maintain desired blood glucose levels in patients with type 1 diabetes. The clinical study results will be presented today in a late-breaking poster session(1) at the American Diabetes Association"s 69th Scientific Sessions in New Orleans.
forex news
News of the day
Iron-Binding Drug Could Help Diabetics Heal Stubborn Wounds, Says Stanford/Einstein Study
A drug used to remove iron from the body could help doctors fight one of diabetes" cruelest complications: poor wound healing, which can lead to amputation of patients" toes, feet and even legs.
Endocrinology

Ultrasound Outperforms Symptom Analysis In Detecting Ovarian Cancer

Doctors at the University of Kentucky Chandler Medical Center-Markey Cancer Center compared symptom analysis to ultrasound in predicting ovarian cancer. They selected 272 women participating in annual trans-vaginal screening (TVS) from 31,748 women enrolled in a free screening project at the university, comparing symptom results to ultrasound and surgical pathology findings. They found TVS performed better than symptoms analysis for detecting malignancies (73.3% versus 20% sensitivity). While symptoms analysis performed better for distinguishing benign tumors (91.3% versus 74.4% specificity), adding symptom analysis to TVS actually resulted in poorer identification of malignancy (sensitivity = 16.7%), even as it improved the ability to distinguish benign tumors (specificity = 97.9%). The authors say the data indicates that while symptoms do identify ovarian malignancies, they are not as accurate as TVS. They add that informative symptoms can be expected to be absent in 80 percent of ovarian malignancies. Article: "The Search for Meaning - Symptoms & TVS Screening." Edward J. Pavlik, Brook A. Saunders, Stacey Doran, Katherine W. McHugh, Frederick R. Ueland, Christopher P. DeSimone, Paul D. DePriest, Rachel A. Ware, Richard J. Kryscio, and John R. van Nagell, Jr. CANCER; Published Online: July 13, 2009 (DOI: 10.1002/cncr.24407); Print Issue Date: August 15, 2009 Editorial: "The search for meaning-symptoms and TVS screening for ovarian cancer - Silent no more." Ilana Cass, M.D. CANCER; Published Online: July 13, 2009 (DOI: 10.1002/cncr.24403); Print Issue Date: August 15, 2009 University of Kentucky Chandler Medical Center Markey Cancer Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):